Results 271 to 280 of about 506,903 (380)

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, EarlyView.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

A Cytochrome P450 AaCP1 Is Required for Conidiation and Pathogenicity in the Tangerine Pathotype of Alternaria alternata. [PDF]

Microorganisms
Fu H, Li W, Tang J.
europepmc   +1 more source

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment

The Journal of Clinical Pharmacology, EarlyView.
Abstract The neurokinin 3 receptor antagonist fezolinetant is an approved treatment for vasomotor symptoms due to menopause. The impacts of hepatic and renal impairment on the pharmacokinetics and safety of a single oral dose of fezolinetant 30 mg were investigated in two independent studies.
Megumi Iwai, Xuegong Wang, Melanie Patton, Lauren Benner, Nakyo Heo, Jace C. Nielsen, Anna Spence, Thomas C. Marbury, Jiayin Huang   +8 more
wiley   +1 more source

The Immature Infant Liver: Cytochrome P450 Enzymes and their Relevance to Vaccine Safety and SIDS Research. [PDF]

Int J Med Sci
Goldman GS, Cheng RZ.
europepmc   +1 more source

Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With Cobicistat

The Journal of Clinical Pharmacology, EarlyView.
Abstract Pharmacokinetic boosting can be a strategy to enhance osimertinib exposure and reduce treatment associated costs. The OSIBOOST trial demonstrated that it was feasible to boost low osimertinib plasma trough levels with cobicistat. The current study aims to establish the equivalent dose of cobicistat boosted osimertinib compared to osimertinib ...
Niels Westra, Paul D. Kruithof, Sander Croes, Robin M. J. M. van Geel, Lizza E. L. Hendriks, Daan J. Touw, Jos G. W. Kosterink, Jasper Stevens, Thijs H. Oude Munnink, Paola Mian   +9 more
wiley   +1 more source

Improving the accuracy of prediction models for small datasets of Cytochrome P450 inhibition with deep learning. [PDF]

J Cheminform
Permadi EE, Watanabe R, Mizuguchi K.
europepmc   +1 more source

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

JCPP Advances, EarlyView.
This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical symptoms of autism spectrum disorder (ASD) for children and adolescents. With limited studies available, there is a need for more high‐power studies for the use of Atomoxetine in children and adolescents with autism spectrum disorder.
Nihit Gupta, Daniel Boyes, Hunter Hanlon‐Taylor, Mayank Gupta   +3 more
wiley   +1 more source

Heterotropic Activation of Cytochrome P450 3A4 by Perillyl Alcohol. [PDF]

Pharmaceutics
Ryu JH, Yu J, Jeon JS, Jo S, Lee SM, Kim H, Park HJ, Oh SJ, Kim SK.   +8 more
europepmc   +1 more source

Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.

, 1996
Veena R. Agarwal, Serdar E. Bulun, M. Leitch, Rachel N. Rohrich, E R Simpson   +4 more
openalex   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Clinical pharmacology and therapy, 2014
K. Crews, A. Gaedigk, A. Gaedigk, H. M. Dunnenberger, J. Leeder, J. Leeder, T. Klein, K. Caudle, Cyrine E. Haidar, D. Shen, J. Callaghan, S. Sadhasivam, C. Prows, E. Kharasch, T. Skaar   +14 more
semanticscholar   +1 more source